Alexza Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:ALXA)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio-0.82
Dividend YieldN/A

About Alexza Pharmaceuticals (OTCMKTS:ALXA)

Alexza Pharmaceuticals logoAlexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company's product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.

Receive ALXA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-0.819672131147541
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($1.22)
Net IncomeN/A
Net Margins-466.94%
Return on EquityN/A
Return on Assets-106.54%


Outstanding SharesN/A

Alexza Pharmaceuticals (OTCMKTS:ALXA) Frequently Asked Questions

What is Alexza Pharmaceuticals' stock symbol?

Alexza Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ALXA."

How were Alexza Pharmaceuticals' earnings last quarter?

Alexza Pharmaceuticals, Inc. (OTCMKTS:ALXA) issued its quarterly earnings data on Wednesday, May, 11th. The healthcare company reported ($0.16) earnings per share (EPS) for the quarter. The healthcare company had revenue of $0.72 million for the quarter. View Alexza Pharmaceuticals' Earnings History.

Who are some of Alexza Pharmaceuticals' key competitors?

How do I buy Alexza Pharmaceuticals stock?

Shares of Alexza Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Alexza Pharmaceuticals?

Alexza Pharmaceuticals' mailing address is 2091 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The healthcare company can be reached via phone at +1-650-9447000.

MarketBeat Community Rating for Alexza Pharmaceuticals (ALXA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Alexza Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alexza Pharmaceuticals (OTCMKTS:ALXA) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Alexza Pharmaceuticals (OTCMKTS:ALXA) Earnings History and Estimates Chart

Earnings by Quarter for Alexza Pharmaceuticals (OTCMKTS:ALXA)

Alexza Pharmaceuticals (OTCMKTS ALXA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2016Q116($0.16)$0.72 millionViewN/AView Earnings Details
3/28/2016Q415($0.37)($0.15)$1.45 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.34)($0.27)$1.60 million$1.77 millionViewN/AView Earnings Details
8/6/2015Q215($0.66)($0.63)$2.31 million$1.88 millionViewN/AView Earnings Details
5/6/2015Q115($0.51)($0.02)$2.23 million$0.71 millionViewN/AView Earnings Details
3/9/2015Q414($0.80)($0.50)$2.99 million$1.45 billionViewN/AView Earnings Details
11/5/2014Q3 2014($0.78)($0.71)$1.52 million$0.46 millionViewN/AView Earnings Details
8/7/2014Q2($0.67)($0.62)$2.24 million$1.50 millionViewListenView Earnings Details
5/5/2014Q1($0.55)($0.55)$2.36 million$2.17 millionViewListenView Earnings Details
3/6/2014Q4 2013($0.71)($0.57)$1.18 million$1.31 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.41)($0.72)$2.30 million$2.17 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.09($0.21)$14.17 million$40.84 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.45)($1.31)$1.00 million$0.73 millionViewListenView Earnings Details
3/26/2013Q4 2012($0.46)($0.65)ViewN/AView Earnings Details
11/7/2012Q312($0.52)$1.86 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.07)($0.58)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.90)($0.50)ViewN/AView Earnings Details
3/12/2012Q4 2011($1.10)($1.24)ViewN/AView Earnings Details
11/7/2011Q3 2011($1.20)($1.90)ViewN/AView Earnings Details
8/8/2011Q2 2011($1.50)($1.26)ViewN/AView Earnings Details
5/9/2011Q1 2011($2.10)($1.40)ViewN/AView Earnings Details
3/15/2011Q4 2010$0.90$4.72ViewN/AView Earnings Details
11/9/2010Q3 2010($2.20)($1.60)ViewN/AView Earnings Details
7/26/2010Q2 2010($2.10)($2.44)ViewN/AView Earnings Details
5/10/2010Q1 2010($3.00)($2.55)ViewN/AView Earnings Details
3/8/2010Q4 2009($2.10)($2.17)ViewN/AView Earnings Details
11/9/2009Q3 2009($2.90)($19.72)ViewN/AView Earnings Details
8/5/2009Q2 2009($3.70)($2.75)ViewN/AView Earnings Details
5/7/2009Q1 2009($2.40)($0.06)ViewN/AView Earnings Details
3/10/2009Q4 2008($4.90)($4.58)ViewN/AView Earnings Details
11/6/2008Q3 2008($4.90)($4.51)ViewN/AView Earnings Details
8/6/2008Q2 2008($4.80)($4.34)ViewN/AView Earnings Details
5/12/2008Q1 2008($4.40)($4.68)ViewN/AView Earnings Details
3/17/2008Q4 2007($3.90)($4.24)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Alexza Pharmaceuticals (OTCMKTS:ALXA) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Alexza Pharmaceuticals (OTCMKTS:ALXA)

No dividend announcements for this company have been tracked by

Insider Trades

Alexza Pharmaceuticals (OTCMKTS ALXA) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Alexza Pharmaceuticals (OTCMKTS:ALXA)

Alexza Pharmaceuticals (OTCMKTS ALXA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2016Ferrer Internacional S GrupoMajor ShareholderBuy19,465,714$0.90$17,519,142.60View SEC Filing  
9/6/2013Gordon RingoldDirectorBuy10,000$4.77$47,700.00View SEC Filing  
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  
7/26/2013Thomas Braxton KingCEOBuy40,000$4.48$179,200.00View SEC Filing  
1/18/2013Lansdowne Partners Austria GmbMajor ShareholderSell125,000$4.75$593,750.00View SEC Filing  
12/27/2012Lansdowne Partners Austria GmbMajor ShareholderBuy72,189$4.85$350,116.65View SEC Filing  
12/26/2012James V CassellaEVPSell4,558$4.90$22,334.20View SEC Filing  
(Data available from 1/1/2013 forward)


Alexza Pharmaceuticals (OTCMKTS ALXA) News Headlines


SEC Filings

Alexza Pharmaceuticals (OTCMKTS:ALXA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Alexza Pharmaceuticals (OTCMKTS:ALXA) Income Statement, Balance Sheet and Cash Flow Statement


Alexza Pharmaceuticals (OTCMKTS ALXA) Stock Chart for Sunday, March, 18, 2018

Loading chart…

This page was last updated on 3/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.